JP2025506729A5 - - Google Patents

Info

Publication number
JP2025506729A5
JP2025506729A5 JP2024549135A JP2024549135A JP2025506729A5 JP 2025506729 A5 JP2025506729 A5 JP 2025506729A5 JP 2024549135 A JP2024549135 A JP 2024549135A JP 2024549135 A JP2024549135 A JP 2024549135A JP 2025506729 A5 JP2025506729 A5 JP 2025506729A5
Authority
JP
Japan
Prior art keywords
isopropyl
acetamide
oxothieno
pyrrolo
triazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/054138 external-priority patent/WO2023156643A1/en
Publication of JP2025506729A publication Critical patent/JP2025506729A/ja
Publication of JP2025506729A5 publication Critical patent/JP2025506729A5/ja
Pending legal-status Critical Current

Links

JP2024549135A 2022-02-21 2023-02-20 チエノピロロトリアジン化合物、それらの調製及びそれらの治療的使用 Pending JP2025506729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22315036 2022-02-21
EP22315036.8 2022-02-21
PCT/EP2023/054138 WO2023156643A1 (en) 2022-02-21 2023-02-20 Thienopyrrolotriazine compounds, their preparation and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2025506729A JP2025506729A (ja) 2025-03-13
JP2025506729A5 true JP2025506729A5 (cg-RX-API-DMAC7.html) 2026-02-27

Family

ID=81326677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549135A Pending JP2025506729A (ja) 2022-02-21 2023-02-20 チエノピロロトリアジン化合物、それらの調製及びそれらの治療的使用

Country Status (11)

Country Link
US (1) US20250129091A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482841B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506729A (cg-RX-API-DMAC7.html)
KR (1) KR20240151767A (cg-RX-API-DMAC7.html)
CN (1) CN118843632A (cg-RX-API-DMAC7.html)
AU (1) AU2023222186A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244475A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010803A2 (cg-RX-API-DMAC7.html)
IL (1) IL314781A (cg-RX-API-DMAC7.html)
MX (1) MX2024010216A (cg-RX-API-DMAC7.html)
WO (1) WO2023156643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375728B (zh) * 2021-12-31 2025-06-10 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168012B2 (en) * 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
US20230203064A1 (en) * 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3

Similar Documents

Publication Publication Date Title
JP4648703B2 (ja) 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
JP2019505541A5 (cg-RX-API-DMAC7.html)
EP1856045B1 (en) 1-acetic acid-indole derivatives with pgd2 antagonist activity
CN1444584A (zh) 依赖细胞周期蛋白的激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]甲酰胺抑制剂
JP2012523440A5 (cg-RX-API-DMAC7.html)
JP2019500352A5 (cg-RX-API-DMAC7.html)
CN1285820A (zh) 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
JP2010516635A5 (cg-RX-API-DMAC7.html)
JP2012515209A5 (cg-RX-API-DMAC7.html)
JP2010518026A5 (cg-RX-API-DMAC7.html)
JP2014531464A (ja) 選択的NK−3受容体拮抗薬としての新規なキラルN−アシル−5,6,7,(8位置換)−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、その医薬組成物、NK−3受容体媒介性障害で使用する方法およびキラル合成
JP2021528446A5 (cg-RX-API-DMAC7.html)
JP2007524710A5 (cg-RX-API-DMAC7.html)
JP2013010790A5 (cg-RX-API-DMAC7.html)
CA2758474A1 (en) Novel p2x7r antagonists and their use
JP2021532124A (ja) Nlrp3インフラマソーム阻害剤
PE20220970A1 (es) Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
US11136309B2 (en) Metalloenzyme inhibitor compounds
JP2012507525A5 (cg-RX-API-DMAC7.html)
JP2024540318A5 (cg-RX-API-DMAC7.html)
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
JP2023507569A5 (cg-RX-API-DMAC7.html)
US6613911B2 (en) Process for preparing arylacetylaminothiazoles
JP2023552838A5 (cg-RX-API-DMAC7.html)
JP2021529168A5 (cg-RX-API-DMAC7.html)